Compare Johnson & Johnson (JNJ) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs ProShares Ultra QQQ ETF — how do they compare? Johnson & Johnson trades at $260.51 (market cap $626.09B), while ProShares Ultra QQQ ETF trades at $92.2. The key difference: Johnson & Johnson pays a 2.06% dividend while ProShares Ultra QQQ ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | QLD | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $100.53 |
52-Week Low | $172.78 | $57.16 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
QLD, the ProShares Ultra QQQ ETF, trades at $92.32, up 0.75% today, reflecting a bullish technical stance with moving averages signaling strength. The fund offers 2x daily leveraged exposure to the Nasdaq-100 index, having delivered over 10,000% total return since inception. Recent institutional buying includes 180 Wealth Advisors increasing its stake by 29.4% in Q2 2026 (SEC Form 13F filing, August 6, 2026).
Outlook remains tied to tech sector performance, with AI optimism and easing geopolitical tensions cited as tailwinds (Zacks Investment Research, May 29, 2026). Key risks include leveraged ETF decay and volatility, evidenced by a 63.80% historical maximum drawdown. The neutral oscillator reading suggests near-term consolidation may precede further moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
